The most appropriate therapeutic strategy for acute lower respiratory tract infections: a Delphi-based approach

References

• Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008 Feb 14;358(7):716–27.10.1056/NEJMra074111
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000 Aug;31(2):347–82.10.1086/313954
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011 Nov;17(Suppl 6):E1–59.10.1111/j.1469-0691.2011.03672.x
   PubMed Web of Science ®Google Scholar
• Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013 Jan;107(1):10–22.10.1016/j.rmed.2012.10.024
   PubMed Web of Science ®Google Scholar
• Di Marco F, Braido F, Santus P, Scichilone N, Blasi F. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage. Eur Rev Med Pharmacol Sci. 2014;18(3):321–32.
   PubMed Web of Science ®Google Scholar
• WHO. WHO global strategy for containment of antimicrobial resistance. Geneva: World Health Organization. 2001.
   Google Scholar
• Blasi F, Concia E, Mazzei T, Moretti AM, Nicoletti G, Novelli A, et al. Role of the oral Beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutics recommendations. J Chemother. 2010 Nov;22(Suppl 1):3–4.10.1179/joc.2010.22.Supplement-1.3
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002 May;121(5):1449–55.
   PubMed Web of Science ®Google Scholar
• Monte SV, Paolini NM, Slazak EM, Schentag JJ, Paladino JA. Costs of treating lower respiratory tract infections. Am J Manag Care. 2008 Apr;14(4):190–6.
   PubMed Web of Science ®Google Scholar
• Morris S, Anderson P, Irwin DE. Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use. PharmacoEconomics. 2002;20(3):153–68.10.2165/00019053-200220030-00002
   PubMed Web of Science ®Google Scholar
• Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000 Oct;32(4):1008–15.
   PubMed Web of Science ®Google Scholar
• Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003 Feb;41(4):376–82.10.1046/j.1365-2648.2003.02537.x
   PubMed Web of Science ®Google Scholar
• Brown AK, O’Connor PJ, Roberts TE, Wakefield RJ, Karim Z, Emery P. Recommendations for musculoskeletal ultrasonography by rheumatologists: setting global standards for best practice by expert consensus. Arthritis Rheum. 2005 Feb 15;53(1):83–92.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010 Mar;137(3):674–91.10.1378/chest.09-1543
   PubMed Web of Science ®Google Scholar
• Zafar SY, Currow DC, Cherny N, Strasser F, Fowler R, Abernethy AP. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol. 2012 Feb;13(2):e77–82.10.1016/S1470-2045(11)70215-7
   PubMed Web of Science ®Google Scholar
• Sanchini A, Campanile F, Monaco M, Cafiso V, Rasigade JP, Laurent F, et al. DNA microarray-based characterisation of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus from Italy. Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1399–408.10.1007/s10096-011-1234-x
   PubMed Web of Science ®Google Scholar
• Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community‐acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010 Jan 15;50(2):202–209.10.1086/648977
   PubMed Web of Science ®Google Scholar
• Del Grosso M, Camilli R, D’Ambrosio F, Petrucci G, Melchiorre S, Moschioni M, et al. Increase of pneumococcal serotype 19A in Italy is due to expansion of the piliated clone ST416/CC199. J Med Microbiol. 2013 Aug;62(Pt 8):1220–5.10.1099/jmm.0.061242-0
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Mameli C, Daprai L, Garlaschi ML, Dilillo D, Bedogni G, et al. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era. Vaccine. 2014 Jan 23;32(5):527–34.
   PubMed Web of Science ®Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Stockholm: ECDC, 2015 November. Report No.
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar;44(Suppl 2):S27–72.10.1086/511159
   PubMed Web of Science ®Google Scholar
• Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, et al. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother. 2008 Oct;20(5):561–9.10.1179/joc.2008.20.5.561
   PubMed Web of Science ®Google Scholar
• Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y, et al. Crystal structure of cefditoren complexed with streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother. 2007 Nov;51(11):3902–7.10.1128/AAC.00743-07
   PubMed Web of Science ®Google Scholar
• Cherkaoui A, Diene SM, Emonet S, Renzi G, Francois P, Schrenzel J. Ampicillin-resistant Haemophilus influenzae isolates in Geneva: serotype, antimicrobial susceptibility, and β-lactam resistance mechanisms. Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):1937–45.10.1007/s10096-015-2435-5
   PubMed Web of Science ®Google Scholar
• Giufrè M, Daprai L, Cardines R, Bernaschi P, Ravà L, Accogli M, et al. Carriage of Haemophilus influenzae in the oropharynx of young children and molecular epidemiology of the isolates after fifteen years of H. influenzae type b vaccination in Italy. Vaccine. 2015 Nov 17;33(46):6227–34.10.1016/j.vaccine.2015.09.082
   PubMed Web of Science ®Google Scholar
• Lâm TT, Claus H, Elias J, Frosch M, Vogel U. Ampicillin resistance of invasive Haemophilus influenzae isolates in Germany 2009–2012. Int J Med Microbiol. 2015 Oct;305(7):748–55.10.1016/j.ijmm.2015.08.028
   PubMed Web of Science ®Google Scholar
• Gonzalez N, Aguilar L, Alou L, Gimenez MJ, Sevillano D, Torrico M, et al. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach. J Antimicrob Chemother. 2009 Jun;63(6):1215–22.10.1093/jac/dkp097
   PubMed Web of Science ®Google Scholar
• Novelli A, Fallani S, Cassetta MI, Conti S. Pharmacokinetics and pharmacodynamics of oral cephalosporins as critical factors in choice of antibiotics. Int J Antimicrob Agents. 2000 Dec;16(4):501–5.10.1016/S0924-8579(00)00285-5
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Elements of design: the knowledge on which we build. Clin Microbiol Infect. 2004 Apr;10(Suppl 2):6–11.10.1111/j.1470-9465.2004.00863.x
   PubMed Web of Science ®Google Scholar
• Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009 Dec;23(4):791–vii.10.1016/j.idc.2009.06.008
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G. Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol (Berlin, Germany). 2005 Jan;20(1):25–9.10.1007/s00467-004-1618-6
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant staphylococcus aureus. Clin Infect Dis. 2011 May 1;52(9):1156–63.10.1093/cid/cir147
   PubMed Web of Science ®Google Scholar
• Soriano F, Granizo JJ, Coronel P, Gimeno M, Rodenas E, Gracia M, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents. 2004 Mar;23(3):296–9.
   PubMed Web of Science ®Google Scholar
• Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64(22):2597–618.10.2165/00003495-200464220-00009
   PubMed Web of Science ®Google Scholar
• Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Saf. 1993 Nov;9(5):346–64.10.2165/00002018-199309050-00004
   PubMed Web of Science ®Google Scholar
• Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994 Apr;33(4):685–706.10.1093/jac/33.4.685
   PubMed Web of Science ®Google Scholar
• Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother. 2000 May 1;45(5):557–9.10.1093/jac/45.5.557
   PubMed Web of Science ®Google Scholar
• Kim GK. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? J Clin Aesthet Dermatol. 2010 Apr;3(4):49–54.
   PubMedGoogle Scholar
• Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Saf. 1993 Aug;9(2):132–42.10.2165/00002018-199309020-00005
   PubMed Web of Science ®Google Scholar
• Mazzei T, Novelli A. Cefditoren Pivoxil. Una nuova cefalosporina orale per il trattamento delle infezioni respiratorie comunitarie. Farmaci & Terapia Int J Drugs Ther. 2004;XXV:1–20.
   Google Scholar
• Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006 Dec 9;333(7580):1193–1197. doi:10.1136/bmj.38993.560984.BE
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995 Jun 26;155(12):1273–6.10.1001/archinte.1995.00430120050006
   PubMedGoogle Scholar
• Menendez R, Montull B, Mendez R. Antibiotic choice, route and durtion: minimising the harm associated with antibiotics. Eur Respir Monogr. 2014;63:155–67.
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J. 2007 Sep;14(Suppl B):5B–32B.10.1155/2007/830570
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016 Feb;47(2):625–37.10.1183/13993003.01170-2015
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015 May;45(5):1446–62.10.1183/09031936.00119114
   PubMed Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009 Oct;64(Suppl 3):iii1–55.
   PubMed Web of Science ®Google Scholar
• GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Full Report. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016; Available from: http://goldcopd.org/
   Google Scholar
• Nozzoli C, Fabbri LM, Gensini G, Consensus Conference. Diagnosi, valutazione di gravità e trattamento della broncopneumopatia cronica ostruttiva e delle malattie croniche concomitanti. Ital J Med. 2012;6 (Suppl): 1–33.
   Google Scholar
• NICE. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Health and Care Excellence (NICE) clinical guideline 101. 2010; Available from: guidance.nice.org.uk/cg101
   Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 Jun;23(6):932–46.10.1183/09031936.04.00014304
   PubMed Web of Science ®Google Scholar
• Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002 Jan;49(1):31–40.10.1093/jac/49.1.31
   PubMed Web of Science ®Google Scholar
• ECDC/EMA. The bacterial challenge: time to react. Technical report. 2009;EMEA/576176/2009.
   Google Scholar
• Gonzalez-Castillo J, Martin-Sanchez FJ, Llinares P, Menendez R, Mujal A, Navas E, et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter. 2014 Mar;27(1):69–86.
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Huang WK, Shyr JM, Lau YJ, Liu YC, Luh KT. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. J Formos Med Assoc. 2004 Sep;103(9):664–70.
   PubMed Web of Science ®Google Scholar